CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $714 | +2.7% | 14,514 | +17.3% | 0.00% | -33.3% |
| Q2 2023 | $695 | +24.1% | 12,372 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $560 | -24.3% | 12,372 | -32.0% | 0.00% | -25.0% |
| Q4 2022 | $740 | -99.9% | 18,207 | 0.0% | 0.00% | -42.9% |
| Q3 2022 | $1,190,000 | +183.3% | 18,207 | +163.2% | 0.01% | +250.0% |
| Q2 2022 | $420,000 | -3.2% | 6,917 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $434,000 | -17.2% | 6,917 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $524,000 | -32.3% | 6,917 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $774,000 | -30.9% | 6,917 | 0.0% | 0.00% | -40.0% |
| Q2 2021 | $1,120,000 | +32.9% | 6,917 | 0.0% | 0.01% | +25.0% |
| Q1 2021 | $843,000 | -20.4% | 6,917 | 0.0% | 0.00% | -20.0% |
| Q4 2020 | $1,059,000 | +82.9% | 6,917 | 0.0% | 0.01% | +66.7% |
| Q3 2020 | $579,000 | +14.0% | 6,917 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $508,000 | – | 6,917 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |